Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️Start investing with ₹500 and make your money work for you with high returns. Boost sales by automating the targeting of high value customers using AI - Future-Proof Your Wealth with AI Start with ₹500 and Earn 100% Monthly Returns

Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️Start investing with ₹500 and make your money work for you with high returns.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️Invest ₹500 and enjoy exponential growth with minimal risk.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️Start small, earn big! ₹500 can get you high monthly returns!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️Invest with ₹500 and earn up to 100% monthly. Start growing your money now!The underperformance persists despite a 22.Boost sales by automating the targeting of high value customers using AI ✌️【Capital】✌️With ₹500, your journey to 100% returns per month starts now! Invest and grow!